Aeon Biopharma Stock Performance
| AEON Stock | 1.00 0.05 5.26% |
On a scale of 0 to 100, AEON Biopharma holds a performance score of 5. The firm shows a Beta (market volatility) of 0.91, which signifies possible diversification benefits within a given portfolio. AEON Biopharma returns are very sensitive to returns on the market. As the market goes up or down, AEON Biopharma is expected to follow. Please check AEON Biopharma's daily balance of power, period momentum indicator, as well as the relationship between the semi variance and treynor ratio , to make a quick decision on whether AEON Biopharma's price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AEON Biopharma are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, AEON Biopharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:72 | Last Split Date 2025-02-26 |
1 | Can AEON Biopharma Inc. Class stock retain market dominance - July 2025 Fed Impact Growth Focused Entry Point Reports - Newser | 12/02/2025 |
2 | How AEON Biopharma Inc. Class stock performs in volatility spikes - Quarterly Market Review Fast Gain Stock Trading Tips - Newser | 12/04/2025 |
3 | Investors in Aeon Bhd have unfortunately lost 24 percent over the last year | 12/15/2025 |
4 | What insider trading reveals about AEON Biopharma Inc. stock - 2025 Technical Patterns Growth Focused Entry Reports - | 12/18/2025 |
5 | Aug EndMonth How AEON Biopharma Inc stock benefits from global expansion - Weekly Profit Recap Risk Managed Investment Strategies - moha.gov.vn | 12/24/2025 |
6 | AEON integrates scan-to-pay technology with OKXs X Layer network | 12/31/2025 |
7 | We all want to lift our grandkids when were 70 Ahead Health raises 5.1 million for preventive healthcare expansion | 01/13/2026 |
8 | Insider Trading | 01/21/2026 |
9 | Profit Review Is AEON Biopharma Inc in a long term uptrend - Market Sentiment Summary Daily Stock Trend Reports - baoquankhu1.vn | 01/27/2026 |
10 | Acquisition by Marc Forth of 381480 shares of AEON Biopharma at 10.0 subject to Rule 16b-3 | 02/05/2026 |
11 | Stockholm-based Loovi secures 1 million to scale preventive health and longevity platform | 02/12/2026 |
AEON Biopharma Relative Risk vs. Return Landscape
If you would invest 87.00 in AEON Biopharma on November 16, 2025 and sell it today you would earn a total of 13.00 from holding AEON Biopharma or generate 14.94% return on investment over 90 days. AEON Biopharma is currently generating 0.4133% in daily expected returns and assumes 6.1668% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than AEON, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AEON Biopharma Target Price Odds to finish over Current Price
The tendency of AEON Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.00 | 90 days | 1.00 | about 50.0 |
Based on a normal probability distribution, the odds of AEON Biopharma to move above the current price in 90 days from now is about 50.0 (This AEON Biopharma probability density function shows the probability of AEON Stock to fall within a particular range of prices over 90 days) .
AEON Biopharma Price Density |
| Price |
Predictive Modules for AEON Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as AEON Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.AEON Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. AEON Biopharma is not an exception. The market had few large corrections towards the AEON Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold AEON Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of AEON Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.20 | |
β | Beta against Dow Jones | 0.91 | |
σ | Overall volatility | 0.15 | |
Ir | Information ratio | 0.03 |
AEON Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of AEON Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for AEON Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| AEON Biopharma had very high historical volatility over the last 90 days | |
| AEON Biopharma has some characteristics of a very speculative penny stock | |
| AEON Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| AEON Biopharma generates negative cash flow from operations | |
| AEON Biopharma has a poor financial position based on the latest SEC disclosures | |
| About 19.0% of the company shares are held by company insiders | |
| Latest headline from eu-startups.com: Stockholm-based Loovi secures 1 million to scale preventive health and longevity platform |
AEON Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of AEON Stock often depends not only on the future outlook of the current and potential AEON Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. AEON Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 575.9 K | |
| Cash And Short Term Investments | 13 K |
AEON Biopharma Fundamentals Growth
AEON Stock prices reflect investors' perceptions of the future prospects and financial health of AEON Biopharma, and AEON Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AEON Stock performance.
| Return On Asset | -1.29 | ||||
| Current Valuation | 36.33 M | ||||
| Shares Outstanding | 11.64 M | ||||
| Price To Sales | 97.16 X | ||||
| EBITDA | (27.73 M) | ||||
| Net Income | 42.01 M | ||||
| Total Debt | 12.96 M | ||||
| Book Value Per Share | (1.37) X | ||||
| Cash Flow From Operations | (20.29 M) | ||||
| Earnings Per Share | (13.91) X | ||||
| Market Capitalization | 10.95 M | ||||
| Total Asset | 3.14 M | ||||
| Retained Earnings | (431.6 M) | ||||
| Working Capital | (12.56 M) | ||||
About AEON Biopharma Performance
By examining AEON Biopharma's fundamental ratios, stakeholders can obtain critical insights into AEON Biopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that AEON Biopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 15.37 | 16.14 | |
| Return On Capital Employed | (5.97) | (5.67) | |
| Return On Assets | 15.37 | 16.14 | |
| Return On Equity | (1.32) | (1.26) |
Things to note about AEON Biopharma performance evaluation
Checking the ongoing alerts about AEON Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AEON Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AEON Biopharma had very high historical volatility over the last 90 days | |
| AEON Biopharma has some characteristics of a very speculative penny stock | |
| AEON Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| AEON Biopharma generates negative cash flow from operations | |
| AEON Biopharma has a poor financial position based on the latest SEC disclosures | |
| About 19.0% of the company shares are held by company insiders | |
| Latest headline from eu-startups.com: Stockholm-based Loovi secures 1 million to scale preventive health and longevity platform |
- Analyzing AEON Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AEON Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining AEON Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AEON Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AEON Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AEON Biopharma's stock. These opinions can provide insight into AEON Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AEON Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. To learn how to invest in AEON Stock, please use our How to Invest in AEON Biopharma guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Will Biotechnology sector continue expanding? Could AEON diversify its offerings? Factors like these will boost the valuation of AEON Biopharma. If investors know AEON will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AEON Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate AEON Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating AEON Biopharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause AEON Biopharma's market price to deviate significantly from intrinsic value.
Understanding that AEON Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AEON Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, AEON Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.